谷丙转氨酶(ALT)水平、饮酒和代谢风险因素与普通人群肝脏相关结果的预后有关

IF 9.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY JHEP Reports Pub Date : 2024-10-01 DOI:10.1016/j.jhepr.2024.101172
Ville Männistö , Veikko Salomaa , Antti Jula , Annamari Lundqvist , Satu Männistö , Markus Perola , Fredrik Åberg
{"title":"谷丙转氨酶(ALT)水平、饮酒和代谢风险因素与普通人群肝脏相关结果的预后有关","authors":"Ville Männistö ,&nbsp;Veikko Salomaa ,&nbsp;Antti Jula ,&nbsp;Annamari Lundqvist ,&nbsp;Satu Männistö ,&nbsp;Markus Perola ,&nbsp;Fredrik Åberg","doi":"10.1016/j.jhepr.2024.101172","DOIUrl":null,"url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>A new nomenclature and subclassification for steatotic liver disease (SLD) was recently introduced. We validated the prognostic value of SLD subclasses in a Finnish population-based cohort and explored the impact of metabolic risk factors and alcohol consumption on liver-related outcomes and death.</div></div><div><h3>Methods</h3><div>The study included 23,910 individuals (47% men, mean age 50.5 ± 14.0 years, BMI 27.0 ± 4.7 kg/m<sup>2</sup>) from the FINRISK and Health 2000 health examination surveys with healthcare registry linkage for severe liver-related outcomes and deaths. SLD was identified by alanine aminotransferase (ALT) levels &gt;20 U/L in women and &gt;30 U/L in men (primary analysis) or fatty liver index (FLI) ≥60 (sensitivity analysis).</div></div><div><h3>Results</h3><div>The prevalence of ALT-defined SLD was 43% (n = 10,380), with subclass rates of 34.5% for metabolic dysfunction-associated steatotic liver disease (MASLD), 4.2% for coexistent MASLD and alcohol-related liver disease (ALD) (i.e., MetALD), and 1.8% for ALD. During a median 13.3-year follow-up, we observed 129 liver-related events. MetALD and ALD increased the age- and sex-adjusted liver-related outcome risk by fourfold (HR 3.83, 95% CI 2.51–5.84, <em>p</em> &lt;0.001) and eightfold (HR 7.90, 95% CI 5.16–12.30, <em>p</em> &lt;0.001), respectively, compared with patients with MASLD. ALD was also associated with the highest risk for non-liver mortality. Metabolic risk factors were present in 93% and 96% of individuals with ALT-defined SLD and ALD, respectively. Alcohol use amplified the risk of liver-related outcomes in individuals with MASLD. Sensitivity analyses by the FLI were similar.</div></div><div><h3>Conclusion</h3><div>SLD is a significant public health concern. Nearly all ALD cases exhibit metabolic risk factors. Among ALT-defined SLD subclasses, ALD presents the highest risk for both liver-related and non-liver-related outcomes. Alcohol use increases the risk of liver-related outcomes in individuals with MASLD.</div></div><div><h3>Impact and implications</h3><div>This study provides important information for physicians, researchers, and patients, demonstrating that the new classification of steatotic liver disease (SLD) has prognostic relevance at the population level. Evaluating the SLD subclass for a patient helps in understanding the magnitude of the risk for liver- and non-liver-related outcomes. In particular, the risks are highest in those with alcohol-related liver disease (ALD), but also increased in individuals with coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) and ALD (MetALD) when compared with those with MASLD. However, alcohol use increased the risk of liver-related outcomes also in individuals with MASLD, highlighting the importance of evaluating alcohol use in every patient with SLD. Nearly all individuals with ALD have metabolic risk factors, and it is important to treat these factors to improve the survival of these patients.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 10","pages":"Article 101172"},"PeriodicalIF":9.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population\",\"authors\":\"Ville Männistö ,&nbsp;Veikko Salomaa ,&nbsp;Antti Jula ,&nbsp;Annamari Lundqvist ,&nbsp;Satu Männistö ,&nbsp;Markus Perola ,&nbsp;Fredrik Åberg\",\"doi\":\"10.1016/j.jhepr.2024.101172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background &amp; Aims</h3><div>A new nomenclature and subclassification for steatotic liver disease (SLD) was recently introduced. We validated the prognostic value of SLD subclasses in a Finnish population-based cohort and explored the impact of metabolic risk factors and alcohol consumption on liver-related outcomes and death.</div></div><div><h3>Methods</h3><div>The study included 23,910 individuals (47% men, mean age 50.5 ± 14.0 years, BMI 27.0 ± 4.7 kg/m<sup>2</sup>) from the FINRISK and Health 2000 health examination surveys with healthcare registry linkage for severe liver-related outcomes and deaths. SLD was identified by alanine aminotransferase (ALT) levels &gt;20 U/L in women and &gt;30 U/L in men (primary analysis) or fatty liver index (FLI) ≥60 (sensitivity analysis).</div></div><div><h3>Results</h3><div>The prevalence of ALT-defined SLD was 43% (n = 10,380), with subclass rates of 34.5% for metabolic dysfunction-associated steatotic liver disease (MASLD), 4.2% for coexistent MASLD and alcohol-related liver disease (ALD) (i.e., MetALD), and 1.8% for ALD. During a median 13.3-year follow-up, we observed 129 liver-related events. MetALD and ALD increased the age- and sex-adjusted liver-related outcome risk by fourfold (HR 3.83, 95% CI 2.51–5.84, <em>p</em> &lt;0.001) and eightfold (HR 7.90, 95% CI 5.16–12.30, <em>p</em> &lt;0.001), respectively, compared with patients with MASLD. ALD was also associated with the highest risk for non-liver mortality. Metabolic risk factors were present in 93% and 96% of individuals with ALT-defined SLD and ALD, respectively. Alcohol use amplified the risk of liver-related outcomes in individuals with MASLD. Sensitivity analyses by the FLI were similar.</div></div><div><h3>Conclusion</h3><div>SLD is a significant public health concern. Nearly all ALD cases exhibit metabolic risk factors. Among ALT-defined SLD subclasses, ALD presents the highest risk for both liver-related and non-liver-related outcomes. Alcohol use increases the risk of liver-related outcomes in individuals with MASLD.</div></div><div><h3>Impact and implications</h3><div>This study provides important information for physicians, researchers, and patients, demonstrating that the new classification of steatotic liver disease (SLD) has prognostic relevance at the population level. Evaluating the SLD subclass for a patient helps in understanding the magnitude of the risk for liver- and non-liver-related outcomes. In particular, the risks are highest in those with alcohol-related liver disease (ALD), but also increased in individuals with coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) and ALD (MetALD) when compared with those with MASLD. However, alcohol use increased the risk of liver-related outcomes also in individuals with MASLD, highlighting the importance of evaluating alcohol use in every patient with SLD. Nearly all individuals with ALD have metabolic risk factors, and it is important to treat these factors to improve the survival of these patients.</div></div>\",\"PeriodicalId\":14764,\"journal\":{\"name\":\"JHEP Reports\",\"volume\":\"6 10\",\"pages\":\"Article 101172\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JHEP Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589555924001769\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHEP Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589555924001769","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景& 目的最近推出了一种新的脂肪性肝病(SLD)命名法和亚分类。我们在芬兰人群队列中验证了SLD亚类的预后价值,并探讨了代谢风险因素和饮酒对肝脏相关结果和死亡的影响。研究纳入了23910人(47%为男性,平均年龄为50.5 ± 14.0岁,体重指数为27.0 ± 4.7 kg/m2),他们来自FINRISK和Health 2000健康体检调查,并与严重肝脏相关结果和死亡的医疗登记进行了连接。结果 ALT 定义的 SLD 患病率为 43%(n = 10,380),代谢功能障碍相关性脂肪性肝病 (MASLD) 的亚类患病率为 34.5%,代谢功能障碍相关性脂肪性肝病和酒精相关性肝病 (ALD) 共存的亚类患病率为 4.2%(即:MetALD),而代谢功能障碍相关性脂肪性肝病 (MASLD) 的亚类患病率为 1.2%、MetALD)的发病率为 4.2%,ALD 的发病率为 1.8%。在中位 13.3 年的随访期间,我们观察到 129 例肝脏相关事件。与 MASLD 患者相比,MetALD 和 ALD 患者经年龄和性别调整后的肝脏相关结果风险分别增加了四倍(HR 3.83,95% CI 2.51-5.84,p <0.001)和八倍(HR 7.90,95% CI 5.16-12.30,p <0.001)。ALD还与最高的非肝死亡风险相关。分别有 93% 和 96% 的 ALT 定义的 SLD 和 ALD 患者存在代谢风险因素。酗酒会增加MASLD患者出现肝脏相关结果的风险。通过FLI进行的敏感性分析结果类似。几乎所有 ALD 病例都有代谢风险因素。在 ALT 定义的 SLD 亚类中,ALD 导致肝脏相关和非肝脏相关结果的风险最高。这项研究为医生、研究人员和患者提供了重要信息,表明新的脂肪性肝病(SLD)分类在人群水平上具有预后相关性。评估患者的 SLD 亚类有助于了解肝脏和非肝脏相关结果的风险程度。尤其是酒精相关性肝病(ALD)患者的风险最高,但同时患有代谢功能障碍相关性脂肪性肝病(MASLD)和ALD(MetALD)的患者与代谢功能障碍相关性脂肪性肝病(MASLD)患者相比,风险也会增加。然而,饮酒也会增加MASLD患者出现肝脏相关结果的风险,这突出了对每一位SLD患者进行饮酒评估的重要性。几乎所有 ALD 患者都有代谢风险因素,因此治疗这些因素对改善这些患者的生存非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population

Background & Aims

A new nomenclature and subclassification for steatotic liver disease (SLD) was recently introduced. We validated the prognostic value of SLD subclasses in a Finnish population-based cohort and explored the impact of metabolic risk factors and alcohol consumption on liver-related outcomes and death.

Methods

The study included 23,910 individuals (47% men, mean age 50.5 ± 14.0 years, BMI 27.0 ± 4.7 kg/m2) from the FINRISK and Health 2000 health examination surveys with healthcare registry linkage for severe liver-related outcomes and deaths. SLD was identified by alanine aminotransferase (ALT) levels >20 U/L in women and >30 U/L in men (primary analysis) or fatty liver index (FLI) ≥60 (sensitivity analysis).

Results

The prevalence of ALT-defined SLD was 43% (n = 10,380), with subclass rates of 34.5% for metabolic dysfunction-associated steatotic liver disease (MASLD), 4.2% for coexistent MASLD and alcohol-related liver disease (ALD) (i.e., MetALD), and 1.8% for ALD. During a median 13.3-year follow-up, we observed 129 liver-related events. MetALD and ALD increased the age- and sex-adjusted liver-related outcome risk by fourfold (HR 3.83, 95% CI 2.51–5.84, p <0.001) and eightfold (HR 7.90, 95% CI 5.16–12.30, p <0.001), respectively, compared with patients with MASLD. ALD was also associated with the highest risk for non-liver mortality. Metabolic risk factors were present in 93% and 96% of individuals with ALT-defined SLD and ALD, respectively. Alcohol use amplified the risk of liver-related outcomes in individuals with MASLD. Sensitivity analyses by the FLI were similar.

Conclusion

SLD is a significant public health concern. Nearly all ALD cases exhibit metabolic risk factors. Among ALT-defined SLD subclasses, ALD presents the highest risk for both liver-related and non-liver-related outcomes. Alcohol use increases the risk of liver-related outcomes in individuals with MASLD.

Impact and implications

This study provides important information for physicians, researchers, and patients, demonstrating that the new classification of steatotic liver disease (SLD) has prognostic relevance at the population level. Evaluating the SLD subclass for a patient helps in understanding the magnitude of the risk for liver- and non-liver-related outcomes. In particular, the risks are highest in those with alcohol-related liver disease (ALD), but also increased in individuals with coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) and ALD (MetALD) when compared with those with MASLD. However, alcohol use increased the risk of liver-related outcomes also in individuals with MASLD, highlighting the importance of evaluating alcohol use in every patient with SLD. Nearly all individuals with ALD have metabolic risk factors, and it is important to treat these factors to improve the survival of these patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JHEP Reports
JHEP Reports GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
12.40
自引率
2.40%
发文量
161
审稿时长
36 days
期刊介绍: JHEP Reports is an open access journal that is affiliated with the European Association for the Study of the Liver (EASL). It serves as a companion journal to the highly respected Journal of Hepatology. The primary objective of JHEP Reports is to publish original papers and reviews that contribute to the advancement of knowledge in the field of liver diseases. The journal covers a wide range of topics, including basic, translational, and clinical research. It also focuses on global issues in hepatology, with particular emphasis on areas such as clinical trials, novel diagnostics, precision medicine and therapeutics, cancer research, cellular and molecular studies, artificial intelligence, microbiome research, epidemiology, and cutting-edge technologies. In summary, JHEP Reports is dedicated to promoting scientific discoveries and innovations in liver diseases through the publication of high-quality research papers and reviews covering various aspects of hepatology.
期刊最新文献
Contents Editorial Board page Copyright and information Contents ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1